Corpus ID: 458713

ABT-378 early access program begins.

  title={ABT-378 early access program begins.},
  journal={AIDS treatment news},
  volume={No 328},
  • Published 1999
  • Medicine
  • AIDS treatment news
The new protease inhibitor ABT-378/r, which is ABT-378 combined with a small amount of Ritonavir, is available to a limited number of patients outside of clinical trials through an Early Access Program. Due to the limited drug availability, ABT-378/r will be offered only to patients who have failed two or more protease inhibitor-containing therapies, and either have a CD4 count less than 50 or have had an opportunistic infection while on highly active antiretroviral therapy. Since ABT-378/r… Expand